Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy
Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • FAQs

    Global Next Generation Sequencing Market size was valued at USD 13.37 Billion in 2024 poised to grow between USD 15.28 Billion in 2025 to USD 44.52 Billion by 2033, growing at a CAGR of 14.3% in the forecast period (2026–2033).

    The global next generation sequencing market outlook is highly competitive, with key players including Illumina, Thermo Fisher Scientific, BGI Genomics, and Oxford Nanopore Technologies. Illumina focuses on expanding its sequencing platforms and acquiring bioinformatics firms. Thermo Fisher leverages strategic collaborations to enhance clinical applications. BGI Genomics emphasizes affordable sequencing services globally, while Oxford Nanopore advances portable, real-time sequencing technologies. Continuous innovation, partnerships, and geographic expansion are core strategies shaping the competitive landscape. 'Illumina Inc. (USA)', 'Thermo Fisher Scientific Inc. (USA)', 'F. Hoffmann-La Roche Ltd. (Switzerland)', 'BGI Genomics Co., Ltd. (China)', 'Oxford Nanopore Technologies plc (United Kingdom)', 'Agilent Technologies Inc. (USA)', 'Pacific Biosciences of California, Inc. (USA)', 'QIAGEN N.V. (Netherlands/Germany)', 'GenapSys Inc. (USA)', 'Eurofins Scientific SE (Luxembourg)', 'Macrogen Inc. (South Korea)', 'Genotypic Technology Pvt. Ltd. (India)', 'Strand Life Sciences Pvt. Ltd. (India)', 'Nabsys Inc. (USA)', 'Takara Bio Inc. (Japan)'

    The emphasis on precision medicine is driving the global next generation sequencing market growth. By enabling comprehensive genetic profiling, next generation sequencing supports personalized treatment plans based on individual genomic variations. This is particularly impactful in oncology, where tailored therapies are improving outcomes. Governments and healthcare providers increasingly adopt next generation sequencing to enhance diagnostic accuracy and therapeutic effectiveness.

    Integration of AI in Next Generation Sequencing Data Analysis: Artificial intelligence is transforming next generation sequencing by automating complex data analysis tasks like variant calling, gene annotation, and sequence alignment. This significantly reduces turnaround time, minimizes human error, and enhances diagnostic precision. AI-powered platforms are driving efficiency, enabling large-scale clinical adoption, and accelerating personalized medicine and genomic research globally.

    Why is Early Adoption of Genomic Technologies Significant for North America?

    Feedback From Our Clients

    Global Next Generation Sequencing Market

    Report ID: SQMIG35D2331

    $3,500
    BUY NOW GET FREE SAMPLE